NCT06346509View on ClinicalTrials.gov

Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study of PORT-77 Administered to Healthy Adult Participants

PHASE1RecruitingINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

April 8, 2024

Primary Completion Date

August 29, 2025

Study Completion Date

August 29, 2025

Conditions
Healthy Adult Participants
Interventions
DRUG

PORT-77

Healthy adult participants will receive a single oral dose of PORT 77.

DRUG

Placebo

Healthy adult participants will receive matching placebo on Day 1.

Trial Locations (1)

85283

RECRUITING

Celerion, Tempe

Sponsors
All Listed Sponsors
lead

Portal Therapeutics, Inc.

INDUSTRY